Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

Launched by PATHOS AI, INC. · Jan 20, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment option for men with metastatic castration-resistant prostate cancer (mCRPC), which is a type of advanced prostate cancer that no longer responds to standard hormone therapy. The study is testing a drug called Pocenbrodib, both on its own and in combination with other medications like Abiraterone acetate, Olaparib, or 177Lu-PSMA-617. The main goal is to find out the best dosage and to see how safe these treatments are, as well as how effective they may be in fighting the cancer.

To participate in this trial, men must be at least 18 years old and have a confirmed diagnosis of prostate adenocarcinoma that has spread to other parts of the body. Participants should not have certain types of cancer cells or liver metastases, and they should not have received certain other cancer treatments in the weeks leading up to the study. If eligible, participants can expect to receive the treatment and be monitored closely for any side effects or changes in their condition. This study is actively recruiting participants, so there may be an opportunity for eligible patients to contribute to important research in prostate cancer treatment.

Gender

MALE

Eligibility criteria

• Key Inclusion Criteria:
• • 1. ≥18 years of age
• • 2. Histologic documentation of prostate adenocarcinoma
• • 3. Metastatic disease, documented by imaging. Imaging performed within 56 days prior to Screening is acceptable
• Key Exclusion Criteria:
• • 1. Current or prior evidence of any small cell or neuroendocrine histology on the most recent prostate biopsy
• • 2. Any liver metastases confirmed by biopsy or evidence of lesions \>1 cm consistent with liver metastases on imaging
• • 3. Intervention with any chemotherapy, investigational agent, or other anticancer drug, including enzalutamide, apalutamide, or darolutamide, 14 days prior to Screening or 5 half-live20.
• • 4. Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the Investigator may interfere with study participation and compliance or place the participant at high risk from treatment-related complicationss from the last dose (whichever is shorter)